Effects of carbamazepine and metabolites on IL-2, IL-5, IL-6, IL-10 and IFN-γ secretion in epileptic patients: The influence of co-medication

Pharmacological Reports

Volumn 63, Issue 1, 2011, Pages 86-94

  Mathieu, Olivier ^a   Picot, Marie Christine ^a   Gelisse, Philippe ^a   Breton, Hélène ^a   Demoly, Pascal ^a   Hillaire Buys, Dominique ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Acridine; Carbamazepine; Cytokines; Epileptic patients; IL 5; Lamotrigine; Valproate

Indexed keywords

ACRIDINE; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; DIBENZAZEPINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; LAMOTRIGINE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EOSINOPHIL; EPILEPSY; EX VIVO STUDY; FEMALE; HUMAN; HUMORAL IMMUNITY; MALE; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL;

EID: 79953211597     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70402-9     Document Type: Article

References (35)

1. Aihara Y, Ito S, Aihara M, Kobayashi Y, Yokota S: Different patterns of cytokines, ECP and immunoglobulin profiles at two adverse drug reactions in a patient. Pediatr Int, 2005, 47, 616-621.
2. Aouam K, Bel Hadj Ali H, Youssef M, Chaabane A, Amri M, Boughattas NA, Zili JE: Carbamazepine-induced DRESS and HHV6 primary infection: the importance of skin tests. Epilepsia, 2008, 49, 1630-1633.
3. Arévalo-Lorido JC, Carretero-Gómez J, Bureo-Dacal JC, Montero-Leal C, Bureo-Dacal P: Antiepileptic drug hypersensitivity syndrome in a patient treated with valproate. Br J Clin Pharmacol, 2003, 55, 415-416. (Pubitemid 36535375)
4. Bernus I, Dickinson RG, Hooper WD, Eadie MJ: The mechanism of the carbamazepine-valproate interaction in humans. Br J Clin Pharmacol, 1997, 44, 21-27. (Pubitemid 27296791)
5. Bocquet H, Bagot M, Roujeau JC: Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg, 1996, 15, 250-257.
6. Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN: Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord, 2004, 82, 309-313. (Pubitemid 39370835)
7. Breton H, Cociglio M, Bressolle F, Peyriere H, Blayac JP, Hillaire-Buys D: Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci, 2005, 828, 80-90. (Pubitemid 41735303)
8. Cogrel O, Beylot-Barry M, Vergier B, Dubus P, Doutre MS, Merlio JP, Beylot C: Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine. Br J Dermatol, 2001, 144, 1235-1238. (Pubitemid 34204219)
9. Conilleau V, Dompmartin A, Verneuil L, Michel M, Leroy D: Hypersensitivity syndrome due to 2 anticonvulsant drugs. Contact Dermatitis, 1999, 41, 141-144. (Pubitemid 29405593)
10. Furst SM, Uetrecht JP: Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem Pharmacol, 1993, 45, 1267-1275. (Pubitemid 23098324)
11. Ganeva M, Gancheva T, Lazarova R, Troeva J, Baldaranov I, Vassilev I, Hristakieva E, Tzaneva V: Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol, 2008, 47, 853-860.
12. Gidal BE, Reiss WG, Liao JS, Pitterle ME: Changes in interleukin-6 concentrations following epilepsy surgery: potential influence on carbamazepine pharmacokinetics. Ann Pharmacother, 1996, 30, 545-546. (Pubitemid 26139256)
13. Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR Jr, Bazil CW: Cross-sensitivity of skin rashes with anti-epileptic drug use. Neurology, 2008, 71, 1527-1534.
14. Ichiyama T, Okada K, Lipton JM, Matsubara T, Hayashi T, Furukawa S: Sodium valproate inhibits production of TNF-α and IL-6 and activation of NF-κB. Brain Res, 2000, 857, 246-251. (Pubitemid 30107811)
15. Kano Y, Shiohara T: The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am, 2009, 29, 481-501.
16. Kocak S, Girisgin SA, Gul M, Cander B, Kaya H, Kaya E: Stevens-Johnson syndrome due to concomitant use of lamotrigine and valproic acid. Am J Clin Dermatol, 2007, 8, 107-111. (Pubitemid 46998554)
17. Lertratanangkoon K, Horning MG: Metabolism of carbamazepine. Drug Metab Disp, 1981, 10, 1-10. (Pubitemid 12177378)
18. Li LM, Russo M, O'Donoghue MF, Duncan JS, Sander JW: Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arq Neuropsiquiatr, 1996, 54, 47-49.
19. Lochmatter P, Beeler A, Kawabata TT, Gerber BO, Pichler WJ: Drug-specific in vitro release of IL-2, IL-5, IL-13 and IFN-γ in patients with delayed-type drug hypersensitivity. Allergy, 2009, 64, 1269-1278.
20. Makis AC, Tzoufi M, Kateri MD, Bourantas KL, Papadopoulou ZL: Valproate-induced eosinophilia in children with epilepsy: role of interleukin-5. J Child Neurol, 2005, 20, 150-152. (Pubitemid 40484857)
21. Mansur AT, Pekcan Yaşar S, Göktay F: Anticonvulsant hypersensitivity syndrome: clinical and laboratory features. Int J Dermatol, 2008, 47, 1184-1189.
22. Marmurowska-Michałowska H, Szuster-Ciesielska A, Kandefer-Szerszeń M, Dubas-Slemp H: The influence of carbamazepine on cytokine and superoxide anion production in blood leukocytes of healthy volunteers. Ann Univ Mariae Curie Sklodowska, 2004, 59, 201-206.
23. Młodzikowska-Albrecht J, Steinborn B, Żarowski M: Cytokines, epilepsy and epileptic drugs - is there a mutual influence? Pharmacol Rep, 2007, 59, 129-138.
24. Morris RG, Black AB, Lam E, Westley IS: Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther Drug Monit, 2000, 22, 656-660.
25. Pacifici R, Paris L, Di Carlo S, Bacosi A, Pichini S, Zuccaro P: Cytokine production in blood mononuclear cells from epileptic patients. Epilepsia, 1995, 36, 384-387.
26. Pearce RE, Lu W, Wang Y, Uetrecht JP, Correia MA, Leeder JS: Pathways of carbamazepine bioactivation in vitro III: The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metab Dispos, 2008, 36, 1637-1649.
27. Pearce RE, Uetrecht JP, Leeder JS: Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos, 2005, 33, 1819-1826.
28. Pearce RE, Vakkalagadda GR, Leeder JS: Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos, 2002, 30, 1170-1179.
29. Peyrière H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac JP, Hillaire-Buys D, Network of the French Pharmacovigilance Centers: Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol, 2006, 155, 422-428. (Pubitemid 44050579)
30. Pichler WJ: Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol, 2002, 2, 301-305.
31. Shiah IS, Yatham LN, Yeh CB, Ravindran AV: Effect of valproate on plasma levels of interleukin-6 in healthy male humans. Int Clin Psychopharmacol, 2005, 20, 295-298. (Pubitemid 41475317)
32. Verrotti A, Basciani F, Trotta D, Greco R, Morgese G, Chiarelli F: Effect of anticonvulsant drugs on interleukins-1, -2 and -6 and monocyte chemoattractant protein-1. Clin Exp Med, 2001, 1, 133-136.
33. Wu Y, Sanderson JP, Farrell J, Drummond NS, Hanson A, Bowkett E, Berry N et al.: Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol, 2006, 118, 233-241. (Pubitemid 43964854)
34. Yun SJ, Lee JB, Kim EJ, Quan G, Kim SJ, Won YH, Lee SC: Drug rash with eosinophilia and systemic symptoms induced by valproate and carbamazepine: formation of circulating auto-antibody against 190-kDa antigen. Acta Derm Venereol, 2006, 86, 241-244. (Pubitemid 43875212)
35. Zarczuk R, Łukasik D, Jedrych M, Borowicz KK: Immunological aspects of epilepsy. Pharmacol Rep, 2010, 62, 592-607.